Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin Plus Epirubicin in Refractory Germ Cell Tumors
NCT00198172Phase 2Terminated
- Sponsor
- Indiana University School of Medicine
- Start
- Oct 2000
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin in germ cell tumor (GCT), sponsored by Indiana University School of Medicine. Primary endpoint: Feasibility and toxicity of combining epirubicin to fixed dose cisplatin. Started Oct 2000; status: terminated.
02
Drugs
epirubicin
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT00198172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00198172.